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Abstract 
Background: Well‑ and dedifferentiated liposarcoma (WD/DDLPS) are rare mesenchymal malignant tumors that 
account for 20% of all sarcomas in adults. The WD form is a low‑grade malignancy with a favourable prognosis which 
may progress to DDLPS, a high‑grade aggressive counterpart. WDLPS is referred to as atypical lipomatous tumour 
(ALT) when localised in extremities, due to its better prognosis. Currently the final differential diagnosis to distinguish 
between more aggressive and less aggressive form is based on post‑surgical histological examination and no molecu‑
lar biomarkers for early detection are available.
Methods: Quantitative polymerase chain reaction (qPCR) analysis of 11 metabolic genes involved in general and 
adipose tissue‑specific metabolism, was performed on ALT (= 8), WDLPS (= 9) and DDLPS (= 20) samples. Subsequent 
statistical analysis was carried out to determine genes that most accurately can predict DDLPS differential diagnosis. 
Selected genes were further validated in a separate cohort by qPCR and the data statistically analysed. Deep sequenc‑
ing was performed on DDLPS specimen from the metastatic patient and on five random WDLPS specimens.
Results: We established a three‑gene signature based on PNPLA2, LIPE and PLIN1, which identified DDLPS with 
100% sensitivity and 90% specificity, even in specimens from the WD component of DDLPS tumors. Interestingly, 
the PNPLA2 gene is deleted in 45% of DDLPS samples analyzed under TCGA project, and the deletion is associated 
with significantly lower PNPLA2 expression level. However, other mechanisms causing loss or downregulation of the 
expression of these three genes may be involved. Moreover, the significantly lower level of PNPLA2 is associated with 
R1 surgical margins, compare to R0 margins, which suggests the more invasive tumor phenotype in the absence of 
PNPLA2.
Conclusions: The identified metabolic signature allows highly accurate differential diagnosis between WD‑ and 
DDLPS even in samples containing lipid droplets, a marker of differentiation, which makes it very suitable for the 
use on biopsies. In respect to the pathogenesis of the disease, our results give a new insight into possible molecular 
mechanisms involved and support the recent observation that deletion of PNPLA2 is a novel factor in liposarcoma 
progression.
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Background
Liposarcoma is a heterogeneous group of malignant 
mesenchymal neoplasms with varying degrees of atypia. 
High-grade malignant liposarcomas, like pleomorphic 
liposarcoma (PLPS), DDLPS and high grade myxoid 
liposarcoma, have a high rate of recurrence and metas-
tasis [1]. Although myxoid liposarcoma respond well to 
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radiotherapy and chemotherapy, the benefit from sys-
temic therapy in PLPS and especially DDLPS is rather 
limited [2, 3]. The well-/dedifferentiated subtype of 
liposarcoma (WD/DDLPS) makes up 50% of all liposar-
comas and occurs mostly in two anatomical sites: in the 
retroperitoneum or in the extremities. In the extremi-
ties WDLPS is referred to as atypical lipomatous tumor 
(ALT), because the prognosis is good. A retroperitoneal/
intra-abdominal location is associated with significantly 
worse outcome, independent of tumor size [4]. The main 
treatment consists of surgical resection with negative 
margins for resectable disease, which is however difficult 
to obtain in the retroperitoneum.
Progression towards the DD form occurs  in 17% of 
patients when WDLPS is located in the  retroperito-
neum and in 4% of cases when WDLPS is located in the 
extremities [5]. DDLPS is reported to metastasize at a 
rate between 13 and 47%, and metastases are fatal, there-
fore DDLPS gives a sixfold higher risk of death compared 
to WDLPS [6, 7].
Tools for differential diagnosis of WD versus DDLPS 
are radiologic examination and macroscopic and histo-
logical evaluation by a pathologist. Although the ampli-
fication of the 12q13–15 region, carrying the MDM2 
andCDK4 genes, is used to distinguish WD/DDLPS and 
ALT from benign lipomas and from other types of lipo-
sarcomas, specific aberrations that can be used to distin-
guish between WDLPS and DDLPS subtypes have not 
been identified so far. Computed tomography (CT) can 
identify non-lipomatous area in a lipomatous tumor but 
does not have the resolution to reveal ongoing dediffer-
entiation processes within adipose-like tissue or to dis-
tinguish dedifferentiated parts of the tumor from stroma 
components, while PET/CT has no routine role for diag-
nosis [8].
The main treatment for WD/DDLPS is surgery. The 
outcome depends on complete surgical resection as 
well as tumor location and histological subtype. Surgi-
cal outcomes are poor for patients with rapidly grow-
ing or incompletely (R1) resected tumors, in particular 
in the retroperitoneum. Wide surgical margins are rec-
ommended, but complete (R0) resection is particularly 
important for DDLPS tumors whenever possible, even at 
the cost of contiguous organ resection. However, because 
of the highly invasive nature of this surgical procedure, 
the post-operatory morbidity and mortality can be an 
issue and there is no consensus among surgeons on the 
best surgical strategy for WDLPS [9–12]. Thus, molecu-
lar biomarkers able to accurately predict the presence of 
DDLPS as early as possible, would be of great value to 
guide the aggressiveness of the surgery.
Here we tested a metabolic gene signature as a bio-
marker for the differential diagnosis of ALT/WD- and 
DDLPS, as well as for its ability to predict malignant evo-
lution towards the DD form. We found that this signature 
allowed the accurate identification of DDLPS among the 
analyzed samples, even in those derived from the WD 
part of DD tumor.
Methods
Patient material
Tumor material was collected after surgery from patients 
that entered the clinic between 2014 and 2017. Patients 
were diagnosed with ALT, WDLPS or DDLPS according 
to the current World Health Organization classification. 
The definition of an ALT or WDLPS was findings of a 
mature lipomatous tumor with some atypical lipoblasts 
with nuclear atypia and cytoplasmic multi-vacuoliza-
tion and/or fibrous areas with atypical spindle cells. For 
DDLPS it was a biphasic appearance, where one com-
ponent is WD and another is non lipomatous area. In 
selected cases, to differentiate from lipomas and other 
sarcomas, analyses of MDM2 amplification were per-
formed. The grading is based on the French system evalu-
ating the mitotic index, the differentiation of the cells and 
the amount of necrosis. The cases were reviewed for diag-
nosis, grade, size, location and MDM2 status if analyzed. 
The project (S-06133) was approved by the Regional Eth-
ical Committee for Southern Norway, and patient partic-
ipation was confirmed by written informed consent. The 
6 DDLPS specimens received from the Leiden University 
Medical Center (LUMC) were anonymized and handled 
according to the ethical guidelines described in the Code 
for Proper Secondary Use of Human Tissue in the Neth-
erlands of the Dutch Federation of Medical Scientific 
Societies, as well as our Norwegian approval. The control 
group included an anonymous pool of human adipose 
tissue (pooled total RNA from 18 individuals of differ-
ent ages and genders; Clontech, cat N. 636558), healthy 
adipose tissue (chest) sample from one anonymous ran-
dom non-sarcoma patient, and 8 lipoma (benign adipose 
tumor) patient samples. All tissues were fresh frozen at 
− 80  °C following surgery. Histological classifications 
were confirmed by a sarcoma reference pathologist.
RNA isolation and quantitative reverse transcription 
polymerase chain reaction (RT‑qPCR)
Total RNA was isolated using Allprep DNA/RNA/
miRNA Kit (Qiagen, cat No. 80224). In four of the 20 
DDLPS samples, total RNA was extracted from the WD 
component. The cDNA synthesis and the RT-qPCR 
were performed using TaqMan gene expression Assay 
(Applied Biosystems). For the normalization, two house-
keeping genes were initially tested, B2M and TUBA1A. 
Both genes gave similar relative expression level of target 
genes. Subsequently, for the space saving, internal control 
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genes were reduced to only B2M, which had lower Ct 
values. All primers were purchased from Applied 
Biosystems.
Statistical analyses
Receiver operator characteristics (ROC) analyses were 
employed to evaluate the ability of univariate and mul-
tivariate models to correctly classify samples in the dis-
covery cohort as either WD- or DDLPS, as defined by the 
pathologist. For each gene, a cut-off value was set as the 
mean of the two least different ΔCt values between the 
WD- and DDLPS groups in the discovery cohort.
Multivariate models were created using binary logistic 
regression with differential diagnosis as binary outcome 
variable (WDLPS vs. DDLPS), and the generated predic-
tive probabilities were evaluated by ROC analysis in R 
(v3.4.3). Hierarchical clustering heatmaps were gener-
ated in R, using the “heatmap.2” package with Euclidean 
measure for distance matrix and complete agglomeration 
method for clustering. Gene ΔCt values were scale nor-
malized (mean = 0 and standard deviation = 1) yielding 
Z-scores in R, and hierarchical clustering was applied 
patient-wise. Wilcoxon rank sum tests were applied to 
evaluate the statistical significance comparing ΔCt values 
from samples with differential histology. χ2 and Student’s 
t-tests were applied evaluate differences in distribution of 
clinicopathological data. A two-sided P value < 0.05 was 
considered statistically significant.
Next generation sequencing data analysis
High quality DNA was isolated using the Promega Wiz-
ard Genomic DNA Purification Kit (Promega, Wiscon-
sin, United States) and the QIAamp DNA FFPE Tissue 
kit (Qiagen, Venlo, Netherlands) as previously described. 
One microgram of genomic DNA was used to produce 
exome-captured sequencing libraries using the Agilent 
SureSelect Human All Exon v5 kit (Agilent Technologies, 
California, United States). Paired-end 100-bp sequencing 
of each exome capture library was done using an Illumina 
HiSeq  2500 instrument and Illumina’s TruSeq SBS v3 
chemistry (Illumina, California, United States).
Reads from tumor and matched normal blood sam-
ple were aligned separately to the human NCBI Build 
GRCh37 reference genome using Novoalign (Novocraft 
Technologies, Selangor, Malaysia) with default param-
eters. PCR duplicates, improper pairs and ambiguously 
mapped reads were removed using in-house scripts. 
SNVs were called using MuTect [13, 14]. Variants annota-
tion was done using Oncotator.
In silico publicly available datasets
Scale-normalized PNPLA2 expression levels, copy num-
ber variation (CNV) data and clinical parameters from 
DDLPS cases within the Adult Soft Tissues Sarcoma 
were downloaded from cBioPortal (refs 23550210 and 
DOI:  https ://doi.org/10.1158/2159-8290.cd-12-0095) 
and visualized using GraphPad Prism 5. Statistical analy-
sis (student’s t-test) on medians and variances was per-
formed in GraphPad Prism 5 [15].
Results
Study design, clinical features and histological analysis
Tissue was collected from 37 patients diagnosed with 
WD/ALT or DDLPS between 2014 and 2017 at Oslo 
University Hospital and Leiden University Medical Cen-
tre. 17 patients were diagnosed with WDLPS/ALT, and 
20  with DDLPS, according to the criteria defined by 
WHO. Eight lipoma specimens from different patients, 
a healthy adipose tissue sample (commercial pooled total 
RNA from 18 individuals), and adipose tissue from one 
random non-sarcoma patients were also included in the 
study as controls (Fig. 1). The median age at presentation 
was 63 years (range 39–80), with similar distribution in 
each group (P = 0.51). Genders were equally represented 
in the groups. All eight ALT were in non-abdominal 
locations such as extremities or thoracic wall, the nine 
WDLPS were located in scrotum (n = 4) or retroperito-
neum (Table 1). 
Microscopic characterization of WDLPS/ALT and 
DDLPS was performed by a sarcoma reference patholo-
gist (BB) on tumor sections after haematoxylin and eosin 
staining. Patients were diagnosed with ALT, WDLPS or 
DDLPS according to the current World Health Organi-
zation classification [16]. The WHO definition of ALT is 
a mesenchymal neoplasm consisting of entirely or partly 
of mature adipocytes with variation in size and at least 
focal nuclear atypia. The finding of multivacuolated lipo-
blasts and hyperchromatic stromal cells contributes to 
the diagnosis. WDLPS/ALT tumors were composed of 
scattered lipoblasts and sheets of adipocytes of variable 
sizes. Cytoplasmic multivacuolization, atypical nuclei 
and deposition of collagen was observed. The diagnosis 
ALT versus WDLS is clinically based on location and the 
possibility to resect the tumor. WDLPS is therefore used 
for tumors in the retroperitoneum and other locations 
where it is difficult to remove the tumor completely, but 
the two entities share the same morphology and genetics.
Classical DDLPS have a biphasic appearance, where 
one component is WD and another is non-lipogenic area 
appearing either in the primary or in a recurrent tumor. 
While the WD components were highly lipogenic, with 
densely packed adipocytes, DD components contained 
spindle-shaped, partly pleomorphic tumor cells, with 
only scarce adipose-like differentiation. In selected cases, 
to differentiate from lipomas and other sarcomas, analy-
ses of MDM2 amplification were performed. Details on 
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each sample and the disease stage are given (Additional 
file 1: Table S1).
The malignancy grading of the tumor was performed 
using the Tumor differentiation score of sarcomas in the 
French Federation of Cancer Centres Sarcoma Group 
System (FNCLCC, Federation Nationale des Centres de 
Lutte Contre le Cancer) [17, 18]. The three-tiered grad-
ing scheme is based on evaluation of tumor differentia-
tion, mitotic count and the amount of tumor necrosis. 
The total score of these parameters are given as the grade. 
Grade two and grade three are considered as high grade 
sarcomas.
The cases were reviewed for diagnosis, grade, size, 
location and MDM2 status if analyzed.
Detection and analysis of expression of metabolic genes
One of the hallmarks of cancer is altered cell metabolism. 
Adipose tissue is a dynamic metabolic tissue character-
ized by the expression of very specific metabolic genes. 
In WDLPS/ALT there are alterations of transcription fac-
tors and cell-cycle related genes, but tissue identity is pre-
served. Instead, in DDLPS dramatic histologic changes 
occur, indicating the deregulation of tissue-specific meta-
bolic genes. Thus, we decided to focus specifically on 
Fig. 1 Study design. Overview of the study flow and of the patient cohorts
Table 1 Clinical characteristics of  the  pooled cohort 
stratified by sample type
WDLPS well-differentiated LPS, ALT atypical lipomatous tumor, DDLPS 
dedifferentiated LPS
§ 2-sided Student’s t-test
* X2 test comparing ALT/WDLPS and DDLPS




N 8 17 20
Age (range) NA 62.8 (45–78) 64.0 (39–80) 0.74§
Gender (%)
 Male 5 (63) 9 (53) 8 (38)
 Female 3 (37) 8 (47) 6 (28) 0.82
 Missing 0 0 6 (30)
Anatomical site (%)
 Abdominal 3 (37) 7 (41) 19 (95) < 0.001*
 Extra‑abdominal 5 (63) 10 (59) 1 (5)
Surgery (%)
 Primary surgery NA 10 (59) 13 (65) 0.7*
 Relapse surgery NA 7 (41) 7 (35)
Metastasis 0 1 NA
Other  cancers# 3 2 NA
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genes involved in fat metabolism, hypothesizing that the 
changes affecting the expression of these genes may pre-
cede major histological changes, allowing the detection 
of the transitional state from WD to higher grade malig-
nancy. In addition to the tissue-specific metabolic genes, 
we included genes involved in antioxidant defense as they 
are strictly connected to cellular metabolic processes.
Gene expression levels of 11 genes coding for pro-
teins involved in adipocyte-specific, lipid and redox 
metabolism were evaluated for their ability to distin-
guish WDLPS/ALT- from DDLPS in a discovery cohort 
(8 WDLPS/ALT and 3 DDLPS samples). The choice to 
include only 3 DDLPS samples in the discovery cohort 
was due to the limited number of samples we had, and 
with the purpose to leave more samples for the validation 
cohort. Gene expression levels of thioredoxin-interacting 
protein (TXIP), superoxide dismutase 2 (SOD2) and glu-
taminase (GLS) showed fair to poor accuracies towards 
distinguishing WD- from DDLPS (ROC AUCs of 0.813, 
0.734 and 0.5, respectively), and were thus disregarded 
from further validation. Although heme oxygenase 1 
(HMOX1) and glucose 6-phosphate dehydrogenase 
(G6PD) were highly accurate (ROC AUCs of 0.937 and 
0.937 respectively), the intra-group variances in ΔCt val-
ues were relatively large (Additional file 2: Figure S1), and 
these genes were therefore also disregarded.
We next proceeded with the evaluation of genes 
involved in fatty acid metabolism, namely stearoyl-CoA 
desaturase 1 (SCD1), fatty acid synthase (FASN), glu-
cose transporter 4 (SLC2A4), hormone-sensitive lipase 
(LIPE), adipose triglyceride lipase (PNPLA2), as well as 
the lipid droplet structural protein perilipin 1 (PLIN1). 
Except for FASN, all showed significant differences in the 
expression level between WD- and DDLPS (Wilcoxon 
rank sum tests P < 0.05; Additional file 2: Figure S1), and 
as each gave sensitivities and specificities of 1 in the dis-
covery cohort (Table 2a) they were all chosen for further 
validation.
Validation was done in an independent cohort consist-
ing of 9 WDLPS/ALT and 17 DDLPS samples, and the 
cutoff values determined in the discovery cohort were 
used to classify the samples based on each gene sepa-
rately. The pre-determined cutoff values generally yielded 
correct classifications, with ROC AUC values rang-
ing from 0.824 to 1.0 (Table  2b). All the genes showed 
statistically significantly different ΔCt values between 
WDLPS and DDLPS in the validation cohort (Additional 
file 3: Figure S2). A binary logistic regression model built 
from the three genes with the highest AUC values (LIPE, 
PNPLA2 and PLIN1, hereby termed 3M) in the discovery 
cohort could correctly classify all the patients in the vali-
dation cohort (AUC = 1.0).
Due to the limited sample size, we chose to reana-
lyze the data after pooling the discovery and validation 
cohorts, including in the analysis two healthy controls 
(commercial pooled total RNA from healthy adipose tis-
sue of 18 individuals and chest adipose tissue from one 
random non-sarcoma patient) and eight lipoma sam-
ples. This strategy allowed us to eventually observe any 
transitional change of the gene expression from healthy 
adipose tissue towards DDLPS. The gene expression pro-
files from healthy adipose tissue samples and lipomas 
Table 2 Sensitivity and specificity values derived from the ROC curve
Observed accuracies (ROC AUC, sensitivity and specificity) of the gene mRNAs at the specified dCt cut-off values in the discovery cohort. Accuracies of the gene 
mRNA’s using the cut-off values in the discovery cohort to correctly classify the samples in the validation cohort
a Excluded specimen M18
Discovery cohort
ALT/WDLPS (N) DDLPS (N) AUC Sens Spec Cut off value (dCt)
GLUT4 8 3 1 1 1 10.99
LIPE 8 3 1 1 1 7.06
ATGL 8 3 1 1 1 5.87
PLIN1 8 3 1 1 1 6.22
SCD1 8 3 1 1 1 6.87
Validation cohort
ALT/WDLPS (N) DDLPS (N)a AUC Sens Spec Correct WDLPS Correct DDLPS
GLUT4 9 17 0.912 0.824 1 9 of 9 14 of 17
LIPE 9 17 1 1 1 9 of 9 17 of 17
ATGL 9 17 0.944 1 0.889 8 of 9 17 of 17
PLIN1 9 17 0.941 0.882 1 9 of 9 15 of 17
SCD1 9 17 0.824 0.647 1 9 of 9 11 of 17
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were indistinguishable. The expression of both LIPE 
and PNPLA2 showed a gradual decrease from lipomas 
towards DDLPS, with significantly lower expression 
already in WDLPS/ALT compared to lipomas (Fig.  2a). 
All five genes had significantly lower expression in 
DDLPS compared to WDLPS (Fig.  2a). Interestingly, 
the expression level of fat-specific gene PLIN1 was not 
changed between lipomas and WDLPS, consistently with 
the presence of comparable amount of fat in these two 
types of specimen. This indicates that the downregulation 
Fig. 2 Expression of lipid metabolic genes is progressively downregulated with dedifferentiation. a Gene expression ΔCt values of the 3M panel 
consisting of LIPE, PNPLA2 and PLIN1 are shown for each patient individually as bee swarm plots from healthy tissue, lipoma, WDLPS and DDLPS. 
Black horizontal lines indicate the median values in each group. Red dots annotate samples extracted from the WD component of tumors from 
patients with a DDLPS diagnosis. Two of the specimens were acquired from the same patient diagnosed with DDLPS, and corresponds to WD 
(blue) and DD (green) components. b Patient‑wise hierarchical clustering heatmap of normalized expression levels of LIPE, PNPLA2 and PLIN1 (3M) 
across adipose controls, lipomas, WDLPS, DDLPS and WD components from DDLPS tumors. Red colors correspond to lowered ΔCt‑values (higher 
expression), and blue corresponds to higher ΔCt values (lower expression). Patients were annotated based on their histological diagnosis. AT 
adipose tissue. HAT healthy adipose tissue, DDLPS = dedifferentiated liposarcoma, M18 metastasis positive patient (the arrow), ns non‑significant, 
WDLPS well‑differentiated liposarcoma
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of PNPLA2 and LIPE in WDLPS cannot be attributed to 
a loss of lipid content. Due to the high accuracies of LIPE, 
PNPLA2 and PLIN1 (the 3M signature) in distinguishing 
WDLPS from DDLPS, we evaluated the expression pat-
terns of only these three genes by hierarchical clustering 
heatmap analysis (Fig.  2b). The normalized expression 
values of these genes showed distinct clustering patterns, 
which distinguished WD from DD LPS samples. Inter-
estingly, in 3 cases where RNA was available only from 
WD component of DDLPS tumors, gene expression pro-
file of the investigated genes clustered together with that 
obtained from DD components of other specimens. The 
only exception was PLIN1, which had higher expression 
in WD component, consistently with the presence of 
lipid droplets (Fig. 2a, red dots). In one case, where RNA 
was available from both WD and DD components of the 
same tumor, the expression level of LIPE and PNPLA2 
again was similar in both components [Fig. 2a, blue dots 
(WD) and green dots (DD)].
Because several adipose tissue-specific metabolic genes 
are directly controlled by the PPARγ master regulator of 
adipocyte differentiation, we measured its expression in 
all the patient specimens to assess whether the observed 
decrease in the expression of metabolic genes could be 
a consequence of reduced PPARG expression. Although 
the majority of DDLPS cases displayed strongly down-
regulated PPARG expression, some cases had PPARG 
expression within the normal range of the WDLPS cases 
(Fig.  3). Among these cases with “WD-like” PPARG 
expression, one specimen belonged to the patient with 
multiple relapses and metastatic disease (referred to as 
M18).
Frequent deletion and clinical relevance of PNPLA2 
in DDLPS
Since WD/DDLPS carry many copy number variants 
(CNVs), we investigated if any of the 3M genes could 
be mutated in  the case M18, for which exome data 
were available. This specimen derived from a patient 
with metastatic disease. The region carrying PNPLA2 
was deleted in this case (Fig. 4, circles), but not in five 
randomly chosen WDLPS samples (data not shown).
We also performed in silico reanalysis of publicly 
available datasets containing sequencing data and clini-
cal parameters of DDLPS cases (TCGA PanCanAtlas, 
https ://www.cbiop ortal .org/study /summa ry?id=sarc_
tcga_pub). First, we checked the copy number varia-
tion (CNVs) and found that PNPLA2 was deleted in 22 
cases (44%). The deletions were hemizygous and were 
associated with significantly lower PNPLA2 expression 
level (P < 0.01) (Fig. 5a). In three cases there was either 
CN gain or gene amplification, which however were not 
associated with gene expression increase.
To assess a clinical relevance of PNPLA2, LIPE and 
PLIN1 expression levels in DDLPS, we investigated 
the clinical parameters in relation to the gene expres-
sion level. Strikingly, we found that samples with R0 
surgical margins had significantly (for both means and 
variances, P < 0.05) higher expression level of PNPLA2, 
while R1 margins were associated with lower PNPLA2 
expression (Fig. 5b). None of the other two genes, LIPE 
and PLIN1, displayed similar associations. Notably, 
based on TCGA data, the oncogenes with the highest 
CNV in DDLPS like MDM2, CDK4 or FRS2 did not 
associate with surgical margins, disease progression or 
overall survival (data not shown).
Collectively, these data highlight PNPLA2 as a prom-
ising diagnostic and prognostic biomarker that is likely 
to play a role in liposarcoma pathogenesis.
Association with clinical parameters
Next, we investigated whether there was a difference 
in the expression levels across non-retroperitoneal and 
retroperitoneal location of ALT/WDLPS tumors in the 
pooled cohort. We found no significant intra-group 
differences between the expression levels of the five 
genes in the different anatomical sites (Additional file 4: 
Figure S3). We then performed binary logistic regres-
sion to evaluate the independence of the five metabolic 
genes of anatomical site. Here, SLC2A4, PNPLA2 and 
SCD1 were independently associated with differential 
diagnosis (OR = 1.09, P = 0.014; OR = 1.52, P = 0.016; 
and OR = 1.45, P = 0.020, respectively). No apparent 
differences in gene expression levels were observed in 
samples from primary and relapse surgeries or across 
gender (data not shown). Anatomical site (abdominal 
vs. non-abdominal) yielded an AUC of 0.75, age (con-
tinuous) 0.59, and the two-combined reached an AUC 
of 0.81 towards distinguishing WDLPS from DDLPS 
(Additional file 5: Figure S4).
Fig. 3 PPARƴ status. Gene expression ΔCt‑values of PPARƴ are shown 
for each patient individually from healthy tissue, lipoma, WDLPS and 
DDLPS. Black horizontal lines indicate the median values in each 
group
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Discussion
Here we report that the combined expression level of 
three adipose tissue-specific metabolic genes, namely 
PNPLA2, LIPE and PLIN1 (the 3M signature), could 
accurately distinguish WDLPS/ALT from DDLPS, and 
we verified this finding in an independent validation 
cohort.
Although it may seem obvious that the loss or down-
regulation of the expression of tissue-specific genes 
merely reflects the dedifferentiation process, a grow-
ing body of evidence strongly suggests that this is not 
the case. Recently, Wu and collaborators demonstrated 
that double knockouts of PNPLA2 and LIPE in mice, 
but not their single knockouts, down-regulated meta-
bolic genes, including those involved in fatty acid and 
lipid metabolism, and the mice spontaneously devel-
oped liposarcoma in brown adipose tissue [19]. Inter-
estingly, the molecular markers of WD/DDLPS, MDM2 
and CDK4, were highly expressed in the adipose tissue 
of double knockout mice.
Another indication of the direct involvement of 
PNPLA2 in liposarcoma pathogenesis comes from a 
recent study where global genome characterization of 
soft tissue sarcomas was performed [15]. In this study, 
the 11p15.5 region, carrying PNPLA2 gene, was recur-
rently deleted in DDLPS samples. The closer look at the 
TCGA DDLPS datasets showed that a “shallow deletion” 
of PNPLA2 corresponded to the significant downregu-
lation of its transcript level, compared to the specimens 
with normal copy number. The recurrent deletion of the 
11p15.5 region in DDLPS was confirmed by a very recent 
study by Beird et  al. [20], comparing CNV profiles of 
DDLPS specimens with the matched WDLPS specimens. 
Strikingly, the deletion of the 11p15.5 region was detected 
only in DDLPS specimens, but not in the WDLPS speci-
mens. Interestingly, when we tested PNPLA2 expression 
Fig. 4 Exome‑based copy number profile of the metastatic specimen. a Genome‑wide copy number profile of the specimen from the metastatic 
patient. The arrow indicates a large deletion on the chromosome 11 and the coordinates of the deleted region and of the PNPLA2 gene location 
(circle). b Copy number profile of the chromosome 11 with the deletion including PNPLA2 indicated by a circle. c High resolution profile of the 
deletion, showing the loss of PNPLA2. The green peaks and valleys indicate counts of exome reads, i.e. copy numbers. Red lines indicate intervening 
sequences not included in the exome
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in WD and DD components of the same tumor, the 
expression was lost in both. It seems likely that PNPLA2 
loss precedes the loss of the WD phenotype, and that 
the deletion of PNPLA2 may be an important event in 
the transition of WDLPS towards DDLPS. Beird et  al. 
also found a low fraction of mutations shared between 
the paired WD and DDLPS subclones, indicative of the 
development of the propensity to dedifferentiate as an 
early process [20].
However, although the deletion of PNPLA2 gene or 
surrounding regions may be a mechanism of gene expres-
sion loss in some samples, the absence of such a deletion 
in other samples suggests the existence of alternative 
mechanisms, like hypermethylation or activation of tran-
scriptional repressors.
In another study by Lyu et  al., knock-out of PLIN1 in 
mice caused down-regulation of adipogenic pathways 
despite the near normal level of PPARγ [21]. Strikingly, 
Horvai and collaborators reported that the PPARγ pro-
tein can be detected in the vast majority of dedifferenti-
ated liposarcomas, with specific nuclear staining in 93% 
of DDLPS tested [22]. Altogether, these data demon-
strate that the loss of these adipose tissue-specific meta-
bolic genes triggers the downregulation of other specific 
metabolic genes independently of the master regulator 
of adipose differentiation PPARγ. In this respect, the loss 
of PNPLA2 expression may be a primary event in the 
DDLPS pathogenesis.
The histological detection of the transformation to 
DDLPS is dependent on the visual observation of per-
haps a minor focal DD component which could easily 
be missed, especially since these tumors are usually very 
large. Importantly, the 3M signature appears to be able to 
provide correct diagnosis of tumors with progression to 
DDLPS even when samples from the phenotypically well-
differentiated parts were investigated. At the same time, 
in those samples, the higher expression of the lipid drop-
let coating protein PLIN1 was consistent with the pres-
ence of lipid droplets, showing that the decrease and loss 
of PNPLA2 and LIPE expression was malignancy-specific 
and not connected to the simple loss of fat part. This 
makes the 3M signature useful for diagnostic biopsies, 
where small samples are randomly collected, although it 
remains to be seen how homogeneously the early loss of 
this signature is distributed in dedifferentiating tumors. 
Moreover, it has been shown that the response of DDLPS 
to chemotherapy is underestimated by current analytical 
tools [23]. This implies that the earliest detection possible 
of the DD component would be important for pharmaco-
logical patient management.
Lipid storage and release from adipose tissue is 
highly coordinated and dependent on several meta-
bolic enzymes, characteristic of mature adipocytes [24]. 
PNPLA2 hydrolyzes triacylglycerols, while LIPE hydro-
lyzes diacylglycerols, both acting coordinately within 
the lipolytic cascade. When these two lipases were 
Fig. 5 PNPLA2 copy number and clinical significance from TCGA datasets. a PNPLA2 shallow deletion (yellow dots), diploid (green dots), copy 
number gain (blue dots) and amplification (brown dot) with corresponding expression levels in DDLPS specimens. PNPLA2 expression in specimens 
with the deletion is significantly lower compared to the diploid counterpart (**P < 0.01). b Complete resection margins are associated with higher 
expression level of PNPLA2 (*P < 0.05). Statistical significance was tested with Student T‑test
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inactivated, lipolysis is almost completely suppressed. 
Because ALT, WD- and DDLPS all have marker chromo-
somes with multiple amplified segments and share the 
same amplification of MDM2 in 12q13–15, their etiol-
ogy appears to be closely related, pointing to a common 
origin. However, the mechanism underlying the transi-
tion from WD- to DDLPS is unknown, although Beird 
et al. identify the frequent loss of the let-7-binding part of 
amplified HMGA2 transcripts in DDLPS to be a possible 
candidate [20, 25]. The new finding reported by Wu et al. 
and our data together indicate that the pathogenic mech-
anism may involve PNPLA2 and LIPE lipases. Impor-
tantly, LIPE is a major retinyl ester hydrolase (REH) in 
white adipose tissue (WAT). REH activity of LIPE-null 
mice was abolished and accompanied by increased levels 
of retinyl esters and decreased levels of retinol, retinal-
dehyde and all-trans RA [26]. Also, the differentiation 
of WAT in LIPE-null mice was suppressed [26]. This is a 
very relevant aspect for the possible implication of LIPE 
in the pathogenic mechanism, as retinoic acid (RA) path-
way has well-established tumor suppressor function and 
its loss contributed to the loss of differentiation in WAT. 
Similarly, a recent review considers non-energetic tumor-
suppressive functions of PNPLA2 in cancer [27].
In addition to the 3M signature, another metabolic gene, 
SCD1, was strongly-down-regulated in DDLPS. However, 
SCD1 displayed more variation across lipoma and WDLPS 
samples, and for this reason it was not included in the final 
diagnostic panel. Yet, in a validation phase on a bigger 
cohort of patients, if necessary, SCD1 may be used together 
with the 3M panel to reinforce the differential diagnosis. 
Although still not validated in a larger cohort, the 3M sig-
nature would be expected to be valuable in the diagnostic 
work-up of WD/DDLPS tumors, together with the rou-
tinely used histological analysis and detection of amplified 
MDM2 by FISH, PCR or immunohistochemistry.
Conclusions
In conclusion, the proposed biomarker represents a new 
insight into the biology of WD/DD liposarcoma and 
offers a potential diagnostic improvement in order to add 
a personalized approach to the surgical procedure, that 
currently totally miss in clinical practice of this disease. 
However, the present study is based on a small cohort 
and needs further validation on bigger cohorts as clinical 
material will be available.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1356 9‑020‑0126‑1.
Additional file 1: Table S1. Additional clinical characteristics of analyzed 
samples. 
Additional file 2: Figure S1. Discovery‑phase investigation of expres‑
sion levels of a priori selected genes. Bee swarm plots showing the ΔCt 
expression levels of HMOX1, GLS, SOD2, G6PD, FASN, TXNIP, SLC2A4, LIPE, 
PNPLA2, PLIN1 and SCD1 across WDLPS and DDLPS tumor samples in the 
discovery cohort. The green dot annotates a sample acquired from the 
WD compartment in a tumor from a patient diagnosed with DDLPS. Sta‑
tistical significance was tested using Wilcoxon rank sum test (ns: P > 0.05; *: 
P < 0.05; **: P < 0.01). 
Additional file 3: Figure S2. Validation‑phase investigation of selected 
genes from the discovery cohort. Bee swarm plots show the ΔCt expres‑
sion levels of SLC2A4, LIPE, PNPLA2, PLIN1 and SCD1 in the validation 
cohort. Red dots annotate samples extracted from the WD component of 
tumors from patients with a DDLPS diagnosis. Statistical significance was 
tested using Wilcoxon rank sum test (***: P < 0.001). 
Additional file 4: Figure S3. Differential gene expression across tumors 
of abdominal and extra‑abdominal origin. Bee swarm plots show the ΔCt 
values for SLC2A4, LIPE, SCD1, PNPLA2 and PLIN1 in WDLPS and DDLPS 
tumors from abdominal and extra‑abdominal sites. The blue dot anno‑
tates the metastasis‑positive patient and red and light blue dots annotate 
samples taken from WD components from patients with DDLPS (light blue 
is from the patient where also a DD sample was extracted and analyzed). 
Abbreviations: ns = non‑significant (P > 0.05). 
Additional file 5: Figure S4. Receiver operator characteristics curves of 
anatomical site, age and the two combined using binary logistic regres‑
sion. Sensitivities and specificities towards distinguishing WDLPS from 
DDLPS are plotted, and the area funder curve (AUC) values for the three 
parameters are shown.
Abbreviations
WDLPS: well‑differentiated liposarcoma; DDLPS: dedifferentiated liposarcoma; 
ALT: atypical lipomatous tumor; PLPS: pleiomorphic liposarcoma; qPCR: quan‑
titative polymerase chain reaction.
Acknowledgements
We thank Dr. Judith Bovée for kindly providing us six dedifferentiated liposar‑
coma patient samples.
Authors’ contributions
AS contributed with the conceptualization of the study, wrote manuscript, 
performed qPCR tests and data analysis. PB performed statistical analysis. BB 
performed histological examination of patient specimens. LMZ performed 
DNA sequencing. OM contributed to the conceptualization of the study and 
manuscript writing. All co‑authors participated in manuscript editing. All 
authors read and approved the final manuscript.
Funding
This project was supported by grants from the Liddy Shriver Sarcoma Initiative 
to the project “Translational Research in Well‑ and De‑differentiated Liposar‑
coma”, and from the Southern and Eastern Norway Regional Health Authority 
(Helse Sør‑Øst) (Grant No. 2013012).
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
The project (S‑06133) was approved by the Regional Ethical Committee 
for Southern Norway, and patient participation was confirmed by written 
informed consent. The 6 DDLPS specimens received from the Leiden Univer‑
sity Medical Center (LUMC) were anonymized and handled according to the 
ethical guidelines described in the Code for Proper Secondary Use of Human 
Tissue in the Netherlands of the Dutch Federation of Medical Scientific Socie‑




The authors declare that they have no competing interests.
Page 11 of 11Serguienko et al. Clin Sarcoma Res            (2020) 10:4  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
Author details
1 Department of Tumor Biology, Institute for Cancer Research, Oslo University 
Hospital, Norwegian Radium Hospital, Ullernchausséen 70, 0379 Oslo, Norway. 
2 Genomics Core Facility, Department of Core Facilities, Institute for Cancer 
Research, Oslo University Hospital, Norwegian Radium Hospital, Ullernchaus‑
séen 70, 0379 Oslo, Norway. 3 Department of Clinical Science, University 
of Bergen and Haukeland University Hospital, 5020 Bergen, Norway. 4 Depart‑
ment of Pathology, Oslo University Hospital, Ullernchausséen 64, 0379 Oslo, 
Norway. 5 Institute of Oral Biology, University of Oslo, Oslo, Norway. 6 Institute 
of Clinical Medicine, University of Oslo, Oslo, Norway. 
Received: 12 September 2019   Accepted: 24 January 2020
References
 1. Karakousis CP, et al. Local recurrence and survival in soft‑tissue sarcomas. 
Ann Surg Oncol. 1996;3(3):255–60.
 2. Italiano A, et al. Advanced well‑differentiated/dedifferentiated liposarco‑
mas: role of chemotherapy and survival. Ann Oncol. 2012;23(6):1601–7.
 3. Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 
2016;122(19):2952–60.
 4. Smith CA, et al. Predicting survival for well‑differentiated liposarcoma: the 
importance of tumor location. J Surg Res. 2012;175(1):12–7.
 5. Mavrogenis AF, et al. Atypical lipomatous tumors/well‑differenti‑
ated liposarcomas: clinical outcome of 67 patients. Orthopedics. 
2011;34(12):e893–8.
 6. Huang HY, et al. Distant metastasis in retroperitoneal dedifferentiated 
liposarcoma is rare and rapidly fatal: a clinicopathological study with 
emphasis on the low‑grade myxofibrosarcoma‑like pattern as an early 
sign of dedifferentiation. Mod Pathol. 2005;18(7):976–84.
 7. Singer S, et al. Histologic subtype and margin of resection predict pattern 
of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 
2003;238(3):358–70.
 8. Messiou C, Morosi C. Imaging in retroperitoneal soft tissue sarcoma. J 
Surg Oncol. 2018;117(1):25–32.
 9. Russo P, et al. Nephrectomy during operative management of retroperi‑
toneal sarcoma. Ann Surg Oncol. 1997;4(5):421–4.
 10. McKiernan J, et al. Natural history of chronic renal insufficiency after 
partial and radical nephrectomy. Urology. 2002;59(6):816–20.
 11. MacNeill AJ, et al. Postoperative Morbidity After Radical Resection of 
Primary Retroperitoneal Sarcoma: a Report From the Transatlantic RPS 
Working Group. Ann Surg. 2018;267(5):959–64.
 12. Raut CP. A rational approach to surgery for retroperitoneal sarcomas: 
extent of resection tailored to histologic findings. Gray Zone Expert 
Opinions. 2017;98:2.
 13. Cibulskis K, et al. Sensitive detection of somatic point mutations 
in impure and heterogeneous cancer samples. Nat Biotechnol. 
2013;31(3):213–9.
 14. Ramos AH, et al. Oncotator: cancer variant annotation tool. Hum Mutat. 
2015;36(4):E2423–9.
 15. Abeshouse A, Adebamowo SN, Akbani R, et al. Comprehensive and 
integrated genomic characterization of adult soft tissue sarcomas. Cell. 
2017;171(4):950–65.
 16. Fletcher C, Hogendoorn P, Mertens F. WHO classification of tumors of soft 
tissue and bone. Lyon: IARC Press; 2013. p. 321–4.
 17. Guillou L, et al. Comparative study of the National Cancer Institute and 
French Federation of Cancer Centers Sarcoma Group grading systems in 
a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 
1997;15(1):350–62.
 18. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch 
Pathol Lab Med. 2006;130(10):1448–53.
 19. Wu JW, et al. Epistatic interaction between the lipase‑encoding 
genes Pnpla2 and Lipe causes liposarcoma in mice. PLoS Genet. 
2017;13(5):e1006716.
 20. Beird HC, et al. Genomic profiling of dedifferentiated liposarcoma 
compared to matched well‑differentiated liposarcoma reveals higher 
genomic complexity and a common origin. Cold Spring Harb Mol Case 
Stud. 2018;4(2):a002386.
 21. Lyu Y, et al. Defective differentiation of adipose precursor cells from 
lipodystrophic mice lacking perilipin 1. PLoS ONE. 2015;10(2):e0117536.
 22. Horvai AE, et al. Immunostaining for peroxisome proliferator gamma 
distinguishes dedifferentiated liposarcoma from other retroperitoneal 
sarcomas. Mod Pathol. 2008;21(5):517–24.
 23. Livingston JA, et al. Role of chemotherapy in dedifferentiated liposar‑
coma of the retroperitoneum: defining the benefit and challenges of the 
standard. Sci Rep. 2017;7(1):11836.
 24. Rutkowski JM, Stern JH, Scherer PE. The cell biology of fat expansion. J 
Cell Biol. 2015;208(5):501–12.
 25. Meza‑Zepeda LA, et al. Ectopic sequences from truncated HMGIC in 
liposarcomas are derived from various amplified chromosomal regions. 
Genes Chromosomes Cancer. 2001;31(3):264–73.
 26. Strom K, et al. Hormone‑sensitive lipase (HSL) is also a retinyl ester hydro‑
lase: evidence from mice lacking HSL. FASEB J. 2009;23(7):2307–16.
 27. Vegliante R, et al. Hints on ATGL implications in cancer: beyond bioener‑
getic clues. Cell Death Dis. 2018;9(3):316.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
